Endocrinology Archives - Page 4 of 7 - Corcept Therapeutics

Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone

May 14, 2024

2024 • AACE 2024

Difficult-to-Control Diabetes: Is Cortisol at Play?

January 8, 2024

• 2023 • Roundtable Discussion

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

July 6, 2023

Simeoli et al. • 2023 • Italian Society of Endocrinology National Congress 2023

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

June 20, 2023

Simeoli et al. • 2023 • ENDO 2023

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

June 16, 2023

Frias et al. • 2023 • ENDO 2023

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

June 9, 2023

Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference

https://corcept.com/wp-content/uploads/2023/07/ECE2023-1.pdf

June 5, 2023

Simeoli et al. • 2023 • European Congress of Endocrinology

An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

June 4, 2023

Badiu et al. • 2023 • European Congress of Endocrinology

https://corcept.com/wp-content/uploads/2023/05/AACE2023-2.pdf

June 3, 2023

Donegan et al. • 2023 • AACE 2023

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

June 1, 2023

Frias et al. • 2023 • AACE 2023